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Introduction
Metabolic syndrome comprises a clustering of car-
dio-metabolic risk factors that include abdominal obe-
sity, impaired glucose tolerance, dyslipidaemia, elevated
blood pressure, and insulin resistance1. The importance
of identifying patients with metabolic syndrome is that
it is associated with an increased risk of both cardio-
vascular disease and type 2 diabetes, and therefore 
provides an opportunity for implementing early
lifestyle change.
C-reactive protein (CRP) is an acute phase protein
synthesized by the liver in response to circulating
inflammatory cytokines such as IL-62. Experimental
studies in vitro suggest that CRP may have a direct role
in the pathogenesis of atherosclerosis2;3. Furthermore,
elevated levels of serum CRP are associated with an
increased risk of cardiovascular disease, including
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acute myocardial infarction and coronary death among
individuals with angina pectoris4. We and others have
shown that metabolic syndrome is associated with high
serum CRP concentrations5.
The heat shock proteins (Hsps) are a family of 20-
25∞∞molecules expressed by cells in response to envi-
ronmental stressors, including high temperature, free
radicals, sheer stress, and toxins, including oxidized-
LDL-C6. Hsps are involved in the renaturation of dam-
aged proteins, allowing them to refold into their native
conformation. High antibody titres to Hsp-60, -65 and
-70 have been reported to be associated with coronary
risk factors7;8, increased risk of cardiovascular dis-
ease9, the severity of cardiovascular, and vascular end-
points in patients with established disease10;11.
Several studies have shown that Hsp27 is over
expressed in cardiac myocytes following ischaemia-
reperfusion, and may potentially have a cardioprotec-
tive effect12.
An increased intake of ω-3 polyunsaturated fatty
acids (PUFA) has been proposed to be beneficial for
cardiovascular disease13. Intervention studies using 
ω-3 PUFA have shown that they have anti-inflamma-
tory effects in patients with chronic inflammatory con-
ditions14. In vivo and in vitro studies have shown that
ω-3 PUFA can modulate the immune system15,16, pro-
bably by decreasing production of prostaglandins such
as PGE2 and leukotrienes such as LTB4. It has also
been demonstrated that ω-3 PUFA can reduce platelet
aggregation, clotting, smooth muscle contraction, and
leukocyte chemotaxis, and can modulate inflammatory
cytokine production and immune function.
Romano et al. have reported that a diet rich in 
saturated fatty acids induces the expression of Hsps
including Hsp-25, -60, and -70 in mice27, and we have
previously reported that Hsp 65 antibody titres rise in
rabbits fed a high-cholesterol diet17. To our knowledge,
there have been no previous reports on the effect of
dietary of ω-3 fatty acids on Hsp-27 antibody titres. In
this current study, we have investigated the effect of
dietary ω-3 fatty acid supplements on several estab-
lished cardiovascular risk factors and also serum anti-
Hsp27 titres in patients with metabolic syndrome.
Methods
SUBJECTS
This study was conducted in Mashhad, Iran. A
total of 120∞∞subjects with metabolic syndrome (defined
using the International Diabetic Federation criteria,
2005), aged 40-70∞∞years, were recruited from one area
of Mashhad. The volunteers had not previously taken
ω-3 fatty acid capsules or other nutritional supple-
ments. However, 14.9% of intervention group subjects
were taking anti-hypertensive medication and 17.0%
of them were being treated with anti-diabetic therapy.
In the control group, 14.3% and 16.7 were taking anti-
hypertensive and anti-diabetic drugs respectively. In
both groups, the treatment did not change during the
course of the study.
Each subject gave informed written consent to 
participate in the study, which was approved by the
Mashhad University of Medical Science Ethics Com-
mittee. Subjects were randomly allocated to either a
group given ω-3 fatty acid capsules (intervention group,
n∞∞=∞∞60), or a control group who were reviewed in the
same way but not given supplements (n∞∞=∞∞60). Subjects
who were∞∞<∞∞40 or∞∞>∞∞70∞∞years old were excluded from the
study, as were subjects who entered the trial but
changed their area of residence. Compliance was mon-
itored by weekly visiting, as assessed by counting
tablets, and subjects who did not take their ω-3 fatty
acid tablets regularly, or, who were intolerant, were
excluded from the study.
OMEGA-3 FATTY ACID TREATMENT
Each ω-3 fatty acid capsule contained 180∞∞mg eicos-
apentaenoic acid (EPA) and 120∞∞mg docosahexaenoic
acid (DHA), (Seven Seas, Ltd Marfleet, Hull, United
Kingdom) and were provided in weekly batches to the
intervention group of subjects to take daily for
6∞∞months. Control subjects did not take any supple-
ments for the duration of the study period. If any sub-
jects were taking other medication, its dose was kept
constant for the duration of the study. Subjects from
both groups were given general dietary advice. Forty-
seven individuals from the intervention group (7∞∞men
and 40 women) and 43 control subjects (4 men and 39
women) completed the study. Subjects, who failed to
take the ω-3 fatty acid capsules regularly, or became
intolerant during the study, were excluded from the
study. Anthropometric and laboratory test data were
collected in both groups of subjects at the end of the
trial.
ANTHROPOMETRIC MEASUREMENTS
Anthropometric parameters including weight,
height, and waist circumference were determined using
a standard protocol. Subjects were asked to breathe
normally, and to breathe out gently at the time of the
measurement. Height and body weight were measured
with the subjects dressed in light clothing after an
overnight fast. The body weight of each subject was
measured with a standard scale to an accuracy
of∞∞±∞∞0.1∞∞kg, and height was measured to an accuracy
of∞∞±∞∞0.1∞∞cm. Body mass index (BMI) was also calcu-
lated. Blood pressure was measured twice while the
patients were seated and rested for 15∞∞minutes, using a
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standard mercury sphygmomanometer calibrated by
the Iranian Institute of Standards and Industrial
Research. The interval between the two blood pressure
measurements was at least 30∞∞minutes, and the average
of the two measurements was taken as the blood pres-
sure. The systolic blood pressure was defined as the
appearance of the first sound (Korotkoff phase 1) and
the diastolic blood pressure was defined as the disap-
pearance of the sound (Korotkoff phase 5) during
deflating of the cuff. The BMI was calculated as weight
(kg) divided by height squared (m2).
COLLECTION OF SERUM SAMPLES
Blood samples were collected in the morning after
an overnight fast from each subject. After being
allowed to clot, the tubes were centrifuged at 2500∞∞rpm
for 15∞∞minutes at room temperature to obtain serum.
Haemolysed samples were excluded from analysis.
Serum was stored at -80°C prior to analysis.
ROUTINE BIOCHEMICAL ANALYSIS
Laboratory data including full fasting lipid profile
comprising total cholesterol, HDL-C, LDL-C, trigly-
cerides and fasting blood sugar (FBS) were determined
for each patient. All of the above were measured by
routine methods. CRP was measured by a high sensi-
tivity PEG-enhanced immunoturbidimetry method
with an Alycon analyzer (ABBOTT, Chicago, IL,
USA).
SERUM HSP 27 ANTIBODY TITRES
Serum Hsp27 antibody titres were measured using
an in-house ELISA. Microtitre plates (Nunc Maxisorp,
Nunc) were coated with 100 ng per well recombinant
human Hsp-27 dissolved in 50 µl carbonate buffer
(pH∞∞=∞∞9.6) incubated for 18∞∞hours at 4°C under humid-
ified conditions. The wells were washed 3∞∞times in wash
buffer (PBS containing 0.05% Tween-20). Non-specific
binding was reduced by blocking each well with 2%
goat serum in PBS and 250 µl added to each well and
incubated for 30∞∞minutes in 37°C and 30∞∞minutes at
room temperature. Wells were washed 3∞∞times with
PBS. Serum was diluted 1:100 with 2% goat serum in
PBS and 100 µl added to each well in duplicate and
incubated for 30∞∞min at room temperature. After wash-
ing (4∞∞times in wash buffer and 2∞∞times in PBS), 100 µl
peroxidase conjugated-goat anti-human IgG (Sigma
Sigma-Aldrich, Inc., USA) diluted 1:500 with 2% goat
serum in PBS, was added to each well, and incubated
for 30∞∞min at room temperature. After washing (4∞∞times
in wash buffer and 2∞∞times in PBS), 100 µl of TMB
substrate (100 µl of 6∞∞mg/ml TMB in DMSO was
added to 10∞∞ml of 50∞∞mM acetate buffer pH 4.5 con-
taining 3 µl H2O2) was added per well and plate incu-
bated for 15∞∞min in the dark at room temperature.
The reaction was terminated by adding 50 µl 2M
HCl per well. Optical density at 450 nm was measured
using a Labsystems iEMS Reader MF microtitre plate
reader with a reference wavelength of 620 or 570 nm.
The within assay and between assay precision was 3.5%
and 5.2%, respectively. After correction for the non-
specific background absorbance (subtracting the
absorbance of uncoated wells from the antigen-coated
wells for each sample) the results were expressed in
optical density units.
STATISTICAL ANALYSIS
Statistical analysis was undertaken with the use of
MINITAB software (release 13; Minitab Inc, State Col-
lege, PA), with determination of descriptive statistics
(i.e, means, medians, SEMs, and interquartile ranges)
for all variables. Data were assessed for normality by
using the Kolmogorov-Smirnov test. Between-group
comparisons of biochemical variables were assessed by
analysis of variance. Categorical data were compared
by using Fisher’s exact test or chi-square test. Values
were expressed as means ± SDs or medians and inter-
quartile ranges (for non-normally distributed data).
Analysis of covariance was used to assess differences
after adjustment for important confounding factors,
such as age and physical activity. The serum titres of
Hsp27 antibody were non-normally distributed and
were therefore logarithmically transformed before para-
metric analysis. For comparison pre- and post-inter-
vention, a paired t-test was used for normally distrib-
uted data and Mann-Whitney U test for non-normally
distributed data.
Results
COMPARISON OF THE BASELINE CHARACTERISTICS OF
INTERVENTION GROUP AND CONTROL SUBJECTS
As would be expected, for subjects with metabolic
syndrome, there was a high mean BMI and prevalence
of lipid abnormalities in both groups at baseline 
as summarized in table 1. The intervention and con-
trol groups did not differ significantly for age,
gender, weight, height, BMI, prevalence of diabetes
(FBS >∞∞7∞∞mmol/L) and hypertension (systolic blood
pressure (SBP) >∞∞140∞∞mmHg or diastolic blood pres-
sure (DBP) >∞∞90∞∞mmHg) or current smoking habit.
Nor did the groups differ with respect to SBP or 
DBP or any of the measured biochemical parameters
(table 1).
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EFFECTS ON CLINICAL PARAMETERS IN THE GROUP
TREATED WITH OMEGA-3 FATTY ACID SUPPLEMENTS
COMPARED WITH THE CONTROL SUBJECTS
On recruitment, each subject was given general
dietary advice. No significant changes were observed
in the frequency of diabetes mellitus (DM), hyperten-
sion (HTN) and smoking habit in either group (table 1,
(P >∞∞0.05). However, the ω-3 fatty acid-treated group
lost significantly more weight (P <∞∞0.05), than the 
control group at 6∞∞months [2.63∞∞kg (3.8%) weight loss
(P <∞∞0.05) vs. 1∞∞kg (1.4%, P >∞∞0.05)]. SBP was also sig-
nificantly lower at the end of the study in the group
receiving omega 3 fatty acid with a mean fall of
7.1∞∞mmHg (5.4%, P <∞∞0.05). The fall in SBP in the con-
trol group (1.8∞∞mm Hg, 1.4%) did not reach statistical
significance (P >∞∞0.05). DBP did not differ significantly
pre and post treatment in both intervention group and
control groups (P >∞∞0.05, table 1).
COMPARISON OF BIOCHEMICAL PARAMETERS IN INTER-
VENTION GROUP AND CONTROL GROUPS
As seen in table 2, there was a statistically significant
reduction in serum fasting triglycerides (17.53%, P <∞∞0.05),
total cholesterol (12.36%, P <∞∞0.05) and LDL-C (20.95%,
P <∞∞0.05) in the subjects who received ω-3 fatty acids.
There was also a significant reduction in hs-CRP
(66.70%, P <∞∞0.01) and Hsp27 antibody titres (57.69%,
P <∞∞0.05) in subjects receiving ω-3 fatty acids, with no
significant change in the control group. Whilst FBS
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Table∞∞1. – Clinical characteristics of the group treated with omega-3 fatty acid supplements and control subjects
Variables Values
Cases Control subjects
Pre Post Pre Post
N 47 47 42 42
Age (years) 53.5∞∞±∞∞12.7 53.5∞∞±∞∞12.7 52.3∞∞±∞∞11.1 52.3∞∞±∞∞11.1
Weight (kg) 68.3∞∞±∞∞11.7 65.7∞∞±∞∞11.6* 69.5∞∞±∞∞14.6 68.5∞∞±∞∞14.1
Height (m) 150.7∞∞±∞∞7.5 150.7∞∞±∞∞7.5 151.3∞∞±∞∞7.3 151.3∞∞±∞∞7.3
BMI (kg/m2) 30.3∞∞±∞∞5.2 29.1∞∞±∞∞5.1* 30.4∞∞±∞∞6.1 29.9∞∞±∞∞5.8
DM (%) 27.7 27.7 30.2 30.2
HTN (%) 31.9 31.9 32.6 32.6
Smokers (%) 4.3 4.3 2.3 2.3
SBP (mmHg) 130.7∞∞±∞∞14.7 123.6∞∞±∞∞23.7* 129.6∞∞±∞∞19.8 127.8∞∞±∞∞16.8
DBP (mmHg) 81.7∞∞±∞∞9.7 81.2∞∞±∞∞9 78.3∞∞±∞∞13.4 82.3∞∞±∞∞9.1
Anti-DM medication (%) 14.9 14.9 14.3 14.3
Anti-hypertensive medication (%) 17.0 17.0 16.7 16.7
Values are expressed as mean ± SD, or percentages. Comparison between pre- and post-treatment was assessed by paired t test for
normally distributed data, or by Mann-Whitney U test for nonparametric data (P*∞∞<∞∞0.05). T test was used for comparison between
pretreatment case and control subjects and no significant differences were observed. BMI = body mass index, DM = diabetes mellitus,
HTN = hypertension, SBP = systolic blood pressure, DBP = diastolic blood pressure.
Table∞∞2. – Biochemical parameters in the case group treated with omega-3 fatty acid supplements and control subjects
Variables Values
Cases (n∞∞=∞∞47) Control subjects (n∞∞=∞∞42)
Pre Post % changes Pre Post % changes
FBS (mmol/l) 6.10∞∞±∞∞2.07 6.34∞∞±∞∞3.16 ∞∞+∞∞3.93 5.91∞∞±∞∞1.73 6.11∞∞±∞∞2.72 ∞∞+∞∞3.38
TC (mmol/l) 5.99∞∞±∞∞1.07 5.24∞∞±∞∞1.15* -12.52 5.75∞∞±∞∞1.04 5.04∞∞±∞∞1.28 -12.35
LDL-C (mmol/l) 3.77∞∞±∞∞0.89 2.98∞∞±∞∞0.79* -20.96 3.71∞∞±∞∞0.72 2.78∞∞±∞∞0.74 -25.07
HDL-C (mmol/l) 1.18∞∞±∞∞0.15 1.23∞∞±∞∞0.16 ∞∞+∞∞4.24 1.12∞∞±∞∞0.19 1.18∞∞±∞∞0.11 ∞∞+∞∞5.36
TG (mmol/l) 1.76 (1.16-2.24) 1.45 (1.04-2.06)* -17.61 1.64 (1.06-2.20) 1.41 (0.96-2.29) -14.02
Hsp 27 antibody titre
(absorbance unit) 0.26 (0.03-0.34) 0.11 (0.03-0.16)* -57.69 0.21 (0.04-0.28) 0.19 (0.03-0.25) -9.52
Hs-CRP (mg/l) 9.37 (5.40-19.39) 3.12 (2.43-9.01)** -66.70 7.73 (5.02-16.32) 6.80 (3.78-9.36) -12.03
Values are expressed as mean ± SD, or percentages. Comparison between pre- and post-treatment was assessed by paired t test for
normally distributed data, or by Mann-Whitney U test for nonparametric data (P*∞∞<∞∞0.05). T-test was used for comparison between
pretreatment case and control subjects and no significant differences were observed. FBS = fasting blood sugar, TC = total cholesterol,
LDL-C = low-density lipoprotein cholesterol, HDL-C = high-density lipoprotein cholesterol, TG = triglycerides, Hsp 27 antibody =
antibody against heat shock protein 27.
and HDL-C did not change significantly in either
group (P∞∞>∞∞0.05) (table 2).
There was a non-significant (P >∞∞0.05) reduction in
some of the clinical and biochemical parameters in the
control group; these included weight (1.43%), BMI
(1.64%), total cholesterol (12.37%), LDL-C (25.20%),
triglycerides (14.55%), hs-CRP (12.03%) and HSP 27
antibody titre (-9.52%), and may relate to the general
dietary advice given to the subjects at the start of the
study (table 2).
Discussion
This is the first reported investigation of the effect
of dietary supplementation of ω-3 on Hsp27 antibody
titres and coronary risk factors in Iranian subjects with
metabolic syndrome. Our results indicated that dietary
supplementation of ω-3 for six months at relatively
low doses can significantly reduce Hsp27 antibody
titres and some features of metabolic syndrome.
EFFECT OF DIETARY SUPPLEMENTATION OF OMEGA-3 ON
LIPID PROFILE
In the present study, beneficial effects of ω-3 PUFA
were noted on lipid profile, specifically TG, and HDL-
C. Consistent with our finding, Harris and Muzio
reported a 32% decrease in plasma triglycerides levels
after taking 64∞∞mg omega-3 fatty acids/kg/body weight
compared to an olive oil placebo daily for 4∞∞weeks in
a double-blind, crossover design. A 17.5% decrease in
plasma triglycerides levels was observed after 6∞∞months
supplementation with omega-3. In another study, there
was a significant decrease in triglycerides and very low
density lipoproteins but a significant increase in total
cholesterol from 5.9 to 6.7∞∞mmol/l after fish oil18.
According to Varga, fish oil therapy causes a marked
decrease in serum triacylglycerol and very low density
lipoprotein levels and moderately increases high den-
sity lipoprotein levels without any adverse effects35. In
our study the percentage changes in total and LDL
cholesterol were similar for the groups and is probably
related to other dietary changes associated with the
advice given to each subjects.
EFFECT OF DIETARY SUPPLEMENTATION OF OMEGA-3 ON
BLOOD PRESSURE
Our results suggest that ω-3∞∞supplementation may
have a beneficial effect on blood pressure. This obser-
vation is in agreement with the results of population-
based intervention studies that have demonstrated that
PUFAs in fish oil lowers blood pressure in subjects
with hypertension19.
In their meta-analysis of 31 trials, Morris et al.20
concluded that the hypotensive effect of fish oil when
used at high doses might be greatest in subjects with
hypertension and in those with established atheroscle-
rotic disease, or hypercholesterolaemia.
In our study the antihypertensive effect of ω-3 fatty
acids may be dependent on their direct vascular effects,
with an associated improvement in endothelial func-
tion. Bao et al. found that the incorporation of fish
into a weight-reducing diet had additive effects in
reducing ambulatory blood pressure, as well as bene-
ficial effects on heart rate, in overweight hypertensive
subjects. These antihypertensive effects were also asso-
ciated with improvements in platelet function, plasma
triglycerides, endothelial function, and inflammatory
cell cytokines21.
EFFECT OF DIETARY SUPPLEMENTATION OF OMEGA-3 ON
PLASMA GLUCOSE
The ω-3 PUFA supplements did not have a signif-
icant effect on plasma glucose. Other reports have
shown a significant increase in fasting glucose after
consumption of fish22 or fish oils23. According to
Puhakainen et al., differences in the dosage of ω-3
PUFA may provide a potential explanation for the dif-
ferences in effects of fish oil on glycaemia24.
EFFECT OF DIETARY SUPPLEMENTATION OF OMEGA-3
FATTY ACIDS ON BODY WEIGHT
We found that dietary ω-3∞∞supplementation may
enhance the reduction in body weight when combined
with lifestyle advice for weight reduction. Dietary ω-3
PUFAs have been reported to reduce body fat deposi-
tion by inducing the expression of genes involved in
lipid metabolism and thermogenesis, increasing total
body heat generation and calorie utilisation25. Because
of their constituent fatty acids, some dietary oils may
have beneficial effects on lipid metabolism and on obe-
sity. Another study has shown that a moderate calorie-
restricted, cod-based diet promoted weight loss, and
was accompanied by a specific improvement in indices
of oxidative stress. The low saturated fat content and
the high fish protein content of this diet may be impor-
tant factors in causing these effects26.
HEAT SHOCK PROTEIN ANTIBODY TITRES, CORONARY
RISK FACTORS AND DIETARY FATTY ACIDS
Several studies suggest that ω-3 fatty acid supple-
mentation may reduce the inflammatory response27. It
is proposed that they do so by several mechanisms in-
cluding: decreasing lymphocyte proliferation, cytokine
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production, natural killer (NK) cytotoxicity and anti-
body production28.
We have previously reported that serum hs-CRP
concentrations are strongly related to serum LDL-C
concentration in serum29. CRP has been proposed to
be actively involved in the initiation of atheromatous
lesion formation30 and the development of the mature
plaque31.
Park et al. found that the plasma levels of Hsp27
were significantly increased in patients with acute coro-
nary syndrome compared with the healthy reference
group, and it has therefore been suggested that circu-
lating levels of Hsp27 antibody titres may be a coro-
nary risk marker16.
Romano et al.28 showed that a diet rich in saturated
fatty acids induces the expression of Hsp-25, -60, and
-70 in mice splenic lymphocytes, and we have previ-
ously shown that antibody titres to Hsp-60, -65 and 
-70 rise following cholesterol feeding in rabbits32. These
associations may be due to a combination of increased
expression of the Hsps and an enhanced immune
response, both of which are associated with a high-
saturated-fat diet. Ghayour-Mobarhan et al. reported
that higher antibody titres to Hsp-60, -65, and -70 are
found in the dyslipidaemic patients, and that other fea-
tures of the metabolic syndrome may be related to a
heightened state of immunoactivation associated with
atherosclerosis in this group36.
The fact that we have not used a double-blind
placebo-controlled trial design for this study does limit
the interpretation of our data. Subjects in the inter-
vention group may have had a more substantial reduc-
tion in weight compared to the control group due to
the so-called ‘Hawthorne effect’37 and a randomized
double-blind placebo-controlled trial would be neces-
sary to confirm our finding.
Conclusion
It appears that a low dose of fish oil supplementa-
tion (1∞∞g/day) for a period of six months improves the
cardiovascular risk profile of subjects with metabolic
syndrome; and has effects on BMI, systolic blood pres-
sure, lipid profile and markers of inflammation and
autoimmunity. This is the first report that fish oil
decreases antibody titres to Hsp27, which is mainly
related to general anti-inflammatory effects of ω-3∞∞sup-
plements. However, these findings will need to be con-
firmed by a formal double-blind placebo-controlled
trial.
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